Ignite Creation Date:
2024-05-05 @ 5:10 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00394251
Status:
COMPLETED
Last Update Posted:
2019-11-25
First Post:
2006-10-30
Brief Title:
Study of Dose-dense Adriamycin Plus Cytoxan AC Followed by Either ABI-007 Abraxane or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Sponsor:
Organization:
Celgene
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
197
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: